ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
이상지질혈증 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 10.6%로 성장할 전망이며, 270억 4,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 지질 저하 요법 진보, 인지도 향상 및 스크리닝 프로그램, 대사 이상 유병률 상승, 의료비 증가, 이상지질혈증 유병률 증가 등의 요인에 기인하고 있습니다. 이 기간 주요 동향으로는 유전자 치료 진전, RNA 기반 치료 혁신, AI 주도 신약의 진전, 맞춤형 의료 발전, 디지털 헬스 모니터링의 진전 등이 있습니다.
비만 인구 증가가 이상지질혈증 시장의 확대를 이끌 것으로 예측됩니다. 건강에 악영향을 미치는 과도한 체지방을 특징으로 하는 비만은 지속되는 에너지 불균형을 일으키는 라이프스타일의 변화로 인해 만연하고 있으며, 완만한 체중 증가와 관련된 건강 문제로 이어지고 있습니다. 비만은 지질 대사를 교란시켜 콜레스테롤과 트리글리세라이드의 이상치를 초래하고 심혈관 질환의 위험을 높임으로써 이상지질혈증의 원인이 됩니다. 예를 들어 스위스에 본부를 둔 정부 간 기관인 세계보건기구(WHO)는 2024년 3월 18세 이상 성인 25억 명을 포함해 전 세계 약 8명 중 1명이 비만의 영향을 받고 있다고 보고했습니다. 게다가 5세 미만 어린이 중 3,700만 명이 비만으로 분류되었습니다. 이 비만율의 상승은 이상지질혈증 시장의 중요한 촉진 요인입니다.
이상지질혈증 시장의 주요 기업은 치료 성적을 개선하고 환자의 어드히어런스를 높이며 여러 지질 불균형을 동시에 대처하기 위한 신흥국 병용요법 개발에 주력하고 있습니다. 선진적 병용요법으로는 2종류 이상의 치료제를 단일 레지멘으로 사용함으로써 유효성을 높이고 부작용을 최소화하며 질환의 다양한 기전을 표적으로 합니다. 예를 들면, 2024년 3월, 미국의 제약회사 Esperion Therapeutics Inc.는, 동사의 의약품인 NEXLETOL(벤페드산)과 NEXLIZET(벤페드산과 에제티미브의 배합제)가 미국 정부 기관인 식품의약국(FDA)으로부터 승인되었다고 발표했습니다. 이러한 선진적인 비스타틴 경구 치료제는 저비중 리포단백 콜레스테롤(LDL-C)을 저하시키고 심혈관 이벤트의 위험을 줄이도록 설계되어 있습니다. 이러한 약제의 라벨이 갱신됨에 따라 콜레스테롤을 저하시키기 위해 일반적으로 처방되는 스타틴 계열 약제와 단독 또는 병용으로 사용할 수 있게 되었습니다. 이 유연성은 스타틴 비내성 환자나 스타틴 이외의 치료법을 선호하는 환자에게 특히 유익합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 이상지질혈증 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 이상지질혈증 시장 : 성장률 분석
세계의 이상지질혈증 시장 실적 : 규모 및 성장(2019-2024년)
세계의 이상지질혈증 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 이상지질혈증 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 이상지질혈증 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
스타틴
담즙산 흡착제
PCSK9 억제제
저분자 간섭 RNA(siRNA)
콜레스테롤 흡수 억제제
피브라토
니아신
오메가3 지방산 유도체
기타
세계의 이상지질혈증 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
경구
비경구
세계의 이상지질혈증 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
약국
온라인 약국
세계의 이상지질혈증 시장 : 스타틴 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
아토르바스타틴
심바스타틴
로스바스타틴
프라바스타틴
세계의 이상지질혈증 시장 : 담즙산 흡착제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
콜레스티라민
콜레세벨람
세계의 이상지질혈증 시장 : PCSK9 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
에볼로쿠맙
아리로쿠맙
세계의 이상지질혈증 시장 : 저분자 간섭 RNA(siRNA) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
잉크리실란
세계의 이상지질혈증 시장 : 콜레스테롤 흡수 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
에제티미브
세계의 이상지질혈증 시장 : 피브레이트 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
페노피브레이트
젬피브로질
세계의 이상지질혈증 시장 : 니아신 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
니코틴산
세계의 이상지질혈증 시장 : 오메가 3 지방산 유도체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
에이코사펜타엔산(EPA)
도코사헥사엔산(DHA)
세계의 이상지질혈증 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
허브 보충제
병용 요법
제7장 지역별 및 국가별 분석
세계의 이상지질혈증 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 이상지질혈증 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
이상지질혈증 시장 : 경쟁 구도
이상지질혈증 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Eli Lilly and Company
Amgen Inc.
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Daiichi Sankyo Company Limited
Zydus Lifesciences Ltd.
Lupin Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc.
Amarin Corporation
Esperion Therapeutics Inc.
Arrowhead Pharmaceuticals Inc.
Outsource Strategies International
Catabasis Pharmaceuticals
NewAmsterdam Pharma Holding BV
JW Pharmaceutical
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
이상지질혈증 시장(2029년) : 새로운 기회를 제공하는 국가
이상지질혈증 시장(2029년) : 새로운 기회를 제공하는 부문
이상지질혈증 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Dyslipidemia is a condition in which the levels of lipids (fats) in the blood become abnormal. The goal of managing dyslipidemia is to regulate lipid levels, reduce the risk of cardiovascular diseases, and enhance heart health through a combination of lifestyle changes, medication, and regular monitoring.
The primary treatment options for dyslipidemia include statins, bile acid sequestrants, PCSK9 inhibitors, small interfering RNA (siRNA), cholesterol absorption inhibitors, fibrates, niacins, omega-3 fatty acid derivatives, and others. Statins are medications that lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is crucial for cholesterol production in the liver. These treatments are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.
The dyslipidemia market research report is one of a series of new reports from The Business Research Company that provides dyslipidemia market statistics, including the dyslipidemia industry global market size, regional shares, competitors with the dyslipidemia market share, detailed dyslipidemia market segments, market trends, and opportunities, and any further data you may need to thrive in the dyslipidemia industry. This dyslipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dyslipidemia market size has grown rapidly in recent years. It will grow from $16.31 billion in 2024 to $18.08 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be attributed to factors such as a rising genetic predisposition, an increasingly sedentary lifestyle, the growing consumption of unhealthy diets, an aging population, and escalating obesity rates.
The dyslipidemia market size is expected to see rapid growth in the next few years. It will grow to $27.04 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth anticipated during the forecast period can be attributed to factors such as advancements in lipid-lowering therapies, increased awareness and screening programs, the rising prevalence of metabolic disorders, higher healthcare expenditure, and the growing prevalence of dyslipidemia. Key trends during this period include advancements in gene therapies, innovations in RNA-based treatments, progress in AI-driven drug discovery, developments in personalized medicine, and advancements in digital health monitoring.
The growing obese population is expected to drive the expansion of the dyslipidemia market. Obesity, characterized by excess body fat that negatively impacts health, is becoming more prevalent due to lifestyle changes that cause prolonged energy imbalances, leading to gradual weight gain and associated health problems. Obesity contributes to dyslipidemia by disrupting lipid metabolism, resulting in abnormal cholesterol and triglyceride levels, which increase the risk of cardiovascular diseases. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide are affected by obesity, including 2.5 billion adults aged 18 and older. Additionally, 37 million children under five years old were classified as overweight. This rising rate of obesity is a significant driver of the dyslipidemia market.
Leading companies in the dyslipidemia market are focusing on developing advanced combination therapies to improve treatment outcomes, enhance patient adherence, and address multiple lipid imbalances simultaneously. Advanced combination therapies involve using two or more therapeutic agents in a single regimen to improve efficacy, minimize side effects, and target various mechanisms of the disease. For instance, in March 2024, Esperion Therapeutics Inc., a US-based pharmaceutical company, announced that its medications NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) were approved by the Food and Drug Administration (FDA), a US government agency. These advanced, non-statin oral treatments are designed to lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events. The updated labels for these drugs allow them to be used alone or in combination with statins, which are commonly prescribed to lower cholesterol. This flexibility is especially beneficial for patients who cannot tolerate statins or prefer non-statin treatment options.
In July 2022, NewAmsterdam Pharma Holding BV, a Netherlands-based biopharmaceutical company focused on treating dyslipidemia, entered into a merger agreement with Frazier Lifesciences Acquisition Corporation. Through this merger, NewAmsterdam aims to develop obicetrapib, a next-generation, low-dose, once-daily CETP inhibitor designed for patients with dyslipidemia who are at high risk for cardiovascular disease. Frazier Lifesciences Acquisition Corporation, a US-based healthcare company, specializes in novel therapeutics.
Major players in the dyslipidemia market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Lupin Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Esperion Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Outsource Strategies International, Catabasis Pharmaceuticals, NewAmsterdam Pharma Holding BV, JW Pharmaceutical.
North America was the largest region in the dyslipidemia market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dyslipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dyslipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dyslipidemia market consists of revenues earned by entities by providing services such as diagnosis, lipid profile testing, medical consultations, lifestyle counseling, prescription, and advanced therapeutic interventions for managing abnormal lipid levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyslipidemia market also includes sales of products such as ezetimibe combination drugs, adenosine triphosphate-citrate lyase (ACL) inhibitors, and bempedoic acid combination drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dyslipidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dyslipidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dyslipidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dyslipidemia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Statins; Bile Acid Sequestrants; PCSK9 Inhibitors; Small Interfering RNA (siRNA); Cholesterol Absorption Inhibitors; Fibrates; Niacins; Omega-3 Fatty Acid Derivatives; Other Treatments
2) By Route Of Administration: Oral; Parental
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Store; Online Pharmacies
Sub Segments:
1) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin
2) By Bile Acid Sequestrants: Cholestyramine; Colesevelam
3) By PCSK9 Inhibitors: Evolocumab; Alirocumab
4) By Small Interfering RNA (siRNA): Inclisiran
5) By Cholesterol Absorption Inhibitors: Ezetimibe
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dyslipidemia Market Characteristics
3. Dyslipidemia Market Trends And Strategies
4. Dyslipidemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Dyslipidemia Growth Analysis And Strategic Analysis Framework
5.1. Global Dyslipidemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Dyslipidemia Market Growth Rate Analysis
5.4. Global Dyslipidemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Dyslipidemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Dyslipidemia Total Addressable Market (TAM)
6. Dyslipidemia Market Segmentation
6.1. Global Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Statins
Bile Acid Sequestrants
PCSK9 Inhibitors
Small Interfering RNA (siRNA)
Cholesterol Absorption Inhibitors
Fibrates
Niacins
Omega-3 Fatty Acid Derivatives
Other Treatments
6.2. Global Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parental
6.3. Global Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Drug Store
Online Pharmacies
6.4. Global Dyslipidemia Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atorvastatin
Simvastatin
Rosuvastatin
Pravastatin
6.5. Global Dyslipidemia Market, Sub-Segmentation Of Bile Acid Sequestrants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cholestyramine
Colesevelam
6.6. Global Dyslipidemia Market, Sub-Segmentation Of PCSK9 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Evolocumab
Alirocumab
6.7. Global Dyslipidemia Market, Sub-Segmentation Of Small Interfering RNA (siRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inclisiran
6.8. Global Dyslipidemia Market, Sub-Segmentation Of Cholesterol Absorption Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ezetimibe
6.9. Global Dyslipidemia Market, Sub-Segmentation Of Fibrates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fenofibrate
Gemfibrozil
6.10. Global Dyslipidemia Market, Sub-Segmentation Of Niacins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nicotinic Acid
6.11. Global Dyslipidemia Market, Sub-Segmentation Of Omega-3 Fatty Acid Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Eicosapentaenoic Acid (EPA)
Docosahexaenoic Acid (DHA)
6.12. Global Dyslipidemia Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Herbal Supplements
Combination Therapies
7. Dyslipidemia Market Regional And Country Analysis
7.1. Global Dyslipidemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Dyslipidemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dyslipidemia Market
8.1. Asia-Pacific Dyslipidemia Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dyslipidemia Market
9.1. China Dyslipidemia Market Overview
9.2. China Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dyslipidemia Market
10.1. India Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dyslipidemia Market
11.1. Japan Dyslipidemia Market Overview
11.2. Japan Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dyslipidemia Market
12.1. Australia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dyslipidemia Market
13.1. Indonesia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dyslipidemia Market
14.1. South Korea Dyslipidemia Market Overview
14.2. South Korea Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dyslipidemia Market
15.1. Western Europe Dyslipidemia Market Overview
15.2. Western Europe Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dyslipidemia Market
16.1. UK Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dyslipidemia Market
17.1. Germany Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dyslipidemia Market
18.1. France Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dyslipidemia Market
19.1. Italy Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dyslipidemia Market
20.1. Spain Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dyslipidemia Market
21.1. Eastern Europe Dyslipidemia Market Overview
21.2. Eastern Europe Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dyslipidemia Market
22.1. Russia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dyslipidemia Market
23.1. North America Dyslipidemia Market Overview
23.2. North America Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dyslipidemia Market
24.1. USA Dyslipidemia Market Overview
24.2. USA Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dyslipidemia Market
25.1. Canada Dyslipidemia Market Overview
25.2. Canada Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dyslipidemia Market
26.1. South America Dyslipidemia Market Overview
26.2. South America Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dyslipidemia Market
27.1. Brazil Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dyslipidemia Market
28.1. Middle East Dyslipidemia Market Overview
28.2. Middle East Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dyslipidemia Market
29.1. Africa Dyslipidemia Market Overview
29.2. Africa Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dyslipidemia Market Competitive Landscape And Company Profiles
30.1. Dyslipidemia Market Competitive Landscape
30.2. Dyslipidemia Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Dyslipidemia Market Other Major And Innovative Companies
31.1. Eli Lilly and Company
31.2. Amgen Inc.
31.3. Viatris Inc.
31.4. Teva Pharmaceutical Industries Ltd.
31.5. Daiichi Sankyo Company Limited
31.6. Zydus Lifesciences Ltd.
31.7. Lupin Pharmaceuticals Inc.
31.8. Alnylam Pharmaceuticals Inc.
31.9. Amarin Corporation
31.10. Esperion Therapeutics Inc.
31.11. Arrowhead Pharmaceuticals Inc.
31.12. Outsource Strategies International
31.13. Catabasis Pharmaceuticals
31.14. NewAmsterdam Pharma Holding BV
31.15. JW Pharmaceutical
32. Global Dyslipidemia Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dyslipidemia Market
34. Recent Developments In The Dyslipidemia Market
35. Dyslipidemia Market High Potential Countries, Segments and Strategies
35.1 Dyslipidemia Market In 2029 - Countries Offering Most New Opportunities
35.2 Dyslipidemia Market In 2029 - Segments Offering Most New Opportunities
35.3 Dyslipidemia Market In 2029 - Growth Strategies
